Biofunctionalization of synthetic materials has broad utility in various biomedical applications but was limited by insu cient e ciency and controllability for bioconjugation. Therefore, we developed a new platform of building synthetic DNA-scaffolds on material surfaces to assemble and organize functional cargos, allowing for more precise control over cargo density and ratio. The adaptation of this technology for biomedical applications requires diverse expertise ranging from materials to bioconjugation chemistry to cell biology, and there are many critical checkpoints to ensure the quality of the platform for the expected biological function. In this protocol, we describe the three key fabrication procedures involved: 1) fabrication of polymeric particles engrafted with DNA-scaffolds (3 days), 2) attachment of functional cargos with complementary DNA strands (3-4 days), and 3) surface assembly control and quanti cation (<1 day). We have also provided additional experimental design considerations for modifying the platform-for example, varying the material composition, size, or cargo types-which may be required for different biological needs. An area of increasing interest is immunomodulation, where immune cells have been recognized for their ability to sense extracellular cues to shape their phenotypic adaptation. We have reported how their modulation can be advanced by this precision biomaterial platform. Here, we exemplify the protocol of primary human T cells activation and identi ed various parameters that can impact T cell ex vivo manufacturing. This protocol will equip investigators with the necessary fabrication procedures and validation assays to design high-delity DNA-scaffolded biomaterials for uses in diverse biomedical applications.